Show simple item record

dc.contributor.authorFazio, N
dc.contributor.authorCarnaghi, C
dc.contributor.authorValle, Juan W
dc.contributor.authorHerbst, F
dc.contributor.authorRidolfi, A
dc.contributor.authorStrosberg, J
dc.contributor.authorKulke, M
dc.contributor.authorPavel, M
dc.contributor.authorYao, J
dc.date.accessioned2019-06-04T09:44:29Z
dc.date.available2019-06-04T09:44:29Z
dc.date.issued2019en
dc.identifier.citationFazio N, Carnaghi C, Valle JW, Herbst F, Ridolfi A, Strosberg J, et al. Relationship between metabolic toxicity and efficacy of everolimus in patients with neuroendocrine tumors (NETs): a pooled analysis from the randomized, phase 3 RADIANT-3, and RADIANT-4 trials. Pancreas. 2019; 48(3):433.en
dc.identifier.urihttp://hdl.handle.net/10541/621840
dc.language.isoenen
dc.titleRelationship between metabolic toxicity and efficacy of everolimus in patients with neuroendocrine tumors (NETs): a pooled analysis from the randomized, phase 3 RADIANT-3, and RADIANT-4 trialsen
dc.typeMeetings and Proceedingsen
dc.contributor.departmentDivision of Gastrointestinal Medical Oncology and Neuroendocrine Tumors, European Institute of Oncology, IEO, Milanen
dc.identifier.journalPancreasen


This item appears in the following Collection(s)

Show simple item record